Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot105810.32687/0869-866X-2022-30-s1-1044-1049Научная статьяFEATURES OF THE USE OF ANTIBACTERIAL DRUGS IN PATIENTS WITH COVID-19KryukovA. V.-KuznetsovaE. V.-TemirbulatovI. I.emirbulatov.ilyas@gmail.comVechorkoV. I.-ZhuravlevaM. V.-Russian Medical Academy of Continuous Professional EducationMunicipal Clinical Hospital No. 15 named after O. M. Filatov of Department of Health of MoscowResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentI. M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)1511202230s11044104917112022Copyright © 2022,2022The review traces the evolution of the section on the use of antibacterial drugs in the temporary guidelines of the Ministry of Health for the treatment of a new coronavirus infection. Diagnostic approaches that play an important role in deciding on the need and duration of antibacterial therapy are presented. Routine use of fluoroquinolones should be restricted due to the adverse safety spectrum. According to existing data, the tactic of short courses of antibacterial therapy for community-acquired pneumonia are not inferior in effectiveness to longer courses. Unjustified prescribing of antibiotics increases the cost of medical care, promotes the selection of resistant pathogens and leads to adverse side effects. Timely updating of clinical recommendations, implementation of programs to control the appointment of antibacterial agents in medical organizations and strengthening the role of the clinical pharmacology service can reduce these adverse eventsCOVID-19COVID-19antibioticsresistancedrug safetyadverse reactionsантибиотикирезистентностьлекарственная безопасностьнежелательные реакции[Huttner B. D., Catho G., Pano-Pardo J. R. et al. COVID-19: don’t neglect antimicrobial stewardship principles! // Clin. Microbiol. Infect. 2020. Vol. 26, N 7. P. 808-810. DOI: 10.1016/j.cmi.2020.04.024][Lai J., Ma S., Wang Y. et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019 // JAMA Netw. Open. 2020. Vol. 3, N 3. P. e203976. DOI: 10.1001/jamanetworkopen.2020.3976][Linder J. A., Doctor J. N., Friedberg M. W. et al. Time of Day and the Decision to Prescribe Antibiotics // JAMA Intern. Med. 2014. Vol. 174, N 12. P. 2029-2031. DOI: 10.1001/jamainternmed.2014.5225][Teixeira R. A., Roque F., Falcão A. et al. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies // Int. J. Antimicrob. Agents. 2013. Vol. 41, N 3. P. 203-212. DOI: 10.1016/J.IJANTIMICAG.2012.09.003][Morris D. E., Cleary D. W., Clarke S. C. Secondary bacterial infections associated with influenza pandemics // Front. Microbiol. 2017. Vol. 8. P. 1041. DOI: 10.3389/fmicb.2017.01041][Uyeki T. M., Bernstein H. H., Bradley J. S. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza // Clin. Infect. Dis. 2019. Vol. 68. P. e1-e47. DOI: 10.1093/cid/ciy866][Beović B., Doušak M., Ferreira-Coimbra J. et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey //j. Antimicrob. Chemother. 2020. Vol. 75, N 11. P. 3386-3390. DOI: 10.1093/JAC/DKAA326][Langford B. J., So M., Raybardhan S. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis // Clin. Microbiol. Infect. 2021. Vol. 27, N 4. P. 520-531. DOI: 10.1016/j.cmi.2020.12.018][Vaughn V. M., Gandhi T. N., Petty L. A. et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with Coronavirus Disease 2019 (COVID-19): a multi-hospital cohort study // Clin. Infect. Dis. 2021. Vol. 72, N 10. P. e533-e541. DOI: 10.1093/cid/ciaa1239][Garcia-Vidal C., Sanjuan G., Moreno-García E. et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study // Clin. Microbiol. Infect. 2021. Vol. 27, N 1. P. 83-88. DOI: 10.1016/j.cmi.2020.07.041][Russell C. D., Fairfield C. J., Drake T. M. et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study // Lancet Microbe. 2021. Vol. 2, N 8. P. e354-e365. DOI: 10.1016/S2666-5247(21)00090-2][Klein E. Y., Monteforte B., Gupta A. et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis // Influenza Other Respir. Viruses. 2016. Vol. 10, N 5. P. 394-403.][Singh V., Upadhyay P., Reddy J., Granger J. SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens // Int. J. Infect. Dis. 2021. Vol. 105. P. 617-620. DOI: 10.1016/j.ijid.2021.02.087][Musuuza J. S., Watson L., Parmasad V. et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis // PLoS One. 2021. Vol. 16, N 5. P. e0251170-e0251170. DOI: 10.1371/journal.pone.0251170][Hodges G., Pallisgaard J., Schjerning Olsen A. M. et al. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohortstudy // BMJ Open. 2020. Vol. 10, N 12. P. e041295. DOI: 10.1136/bmjopen-2020-041295][Kooistra E. J., van Berkel M., van Kempen N. F. et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients // Crit. Care. 2021. Vol. 25, N 1. P. 1-12. DO: 10.1186/s13054-021-03717-z][Wey E. Q., Bristow C., Nandani A. et al. Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19 //j. Infect. 2021. Vol. 83, N 5. P. 607-635. DOI: 10.1016/j.jinf.2021.08.017][Metlay J. P., Waterer G. W., Long A. C. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America // Am. J. Respir. Crit. Care Med. 2019. Vol. 200, N 7. P. e45-e67. DOI: 101164/rccm201908-1581ST][Self W. H., Balk R. A., Grijalva C. G. et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia // Clin. Infect. Dis. 2017. Vol. 65, N 2. P. 183-190. DOI: 10.1093/cid/cix317][May M., Chang M., Dietz D. et al. Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019 // Antimicrob. Agents Chemother. 2021. Vol. 65, N 4. P. e02167-e021620. DOI: 10.1128/AAC.02167-20][Calderon M., Li A., Bazo-Alvarez J. C. et al. Evaluation of procalcitonin-guided antimicrobial stewardship in patients admitted to hospital with COVID-19 pneumonia. JAC-antimicrob. Resist. 2021. Vol. 3, N 3. P. dlab133-dlab133. DOI: 10.1093/jacamr/dlab133][Hughes S., Mughal N., Moore L. S. P. Procalcitonin to Guide Antibacterial Prescribing in Patients Hospitalised with COVID-19 // Antibiotics. 2021. Vol. 10. N 9. P. 1119. DOI: 10.3390/antibiotics10091119][Mason C. Y., Kanitkar T., Richardson C. J. et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics //j. Antimicrob. Chemother. 2021. Vol. 76, N 5. P. 1323-1331. DOI: 10.1093/JAC/DKAA563][Mega J. L., Simon T., Collet J. P. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI // JAMA. 2010. Vol. 304, N 16. P. 1821-1830. DOI: 10.1001/jama.2010.1543][Horita N., Otsuka T., Haranaga S. et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis // Respirology. 2016. Vol. 21, N 7. P. 1193-1200. DOI: 10.1111/RESP.12835][Shumilak G., Sligl W. I. Moving past the routine use of macrolides-reviewing the role of combination therapy in community-acquired pneumonia // Curr. Infect. Dis. Rep. 2018. Vol. 20, N 11. P. 45. DOI: 10.1007/s11908-018-0651-8][Eliakim-Raz N., Robenshtok E., Shefet D. et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults // Cochrane Database Syst. Rev. 2012. Vol. 2012, N 9. P. CD004418. DOI: 10.1002/14651858.CD004418.pub4][Gardiner S. J., Gavranich J. B., Chang A. B. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children // Cochrane Database Syst. Rev. 2015. Vol. 1. P. CD004875. DOI: 10.1002/14651858.CD004875.pub5][Kovaleva A., Remmelts H. H.F., Rijkers G. T. et al. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review //j. Antimicrob. Chemother. 2012. Vol. 67, N 3. P. 530-540. DOI: 10.1093/jac/dkr520][Raz-Pasteur A., Shasha D., Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis // Int. J. Antimicrob. Agents. 2015. Vol. 46, N 3. P. 242-248. DOI: 10.1016/J.IJANTIMICAG.2015.04.010][FDA. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics (accessed: 27.09.2021).][Inghammar M., Svanström H., Melbye M. et al. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study // BMJ. 2016. Vol. 352. P. i843. DOI: 10.1136/BMJ.I843][Dingle K. E., Didelot X., Quan T. P. et al. Effects of control interventions on Clostridium difficile infection in England: an observational study // Lancet Infect. Dis. 2017. Vol. 17, N 4. P. 411-421. DOI: 10.1016/S1473-3099(16)30514-X][FDA. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain (accessed: 27.09.2021).][Jin B., Ni H. C., Shen W. et al. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel // Mol. Biol. Rep. 2011. Vol. 38, N 3. P. 1697-1702. DOI: 10.1007/s11033-010-0282-0][Llewelyn M. J., Fitzpatrick J. M., Darwin E. et al. The antibiotic course has had its day // BMJ. 2017. Vol. 358. P. j3418. DOI: 10.1136/bmj.j3418][Spellberg B. The new antibiotic mantra - «Shorter Is Better» // JAMA Intern. Med. 2016. Vol. 176, N 9. P. 1254-1255. DOI: 10.1001/jamainternmed.2016.3646][Dinh A., Ropers J., Duran C. et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial // Lancet. 2021. Vol. 397, N 10280. P. 1195-1203. DOI: 10.1016/S0140-6736(21)00313-5]